Respiratory Medicine
Volume 97, Issue 1 , Pages 1-11 , January 2003

Cost–effectiveness analysis of inhaled corticosteroids in asthma: a review of the analytical standards

Received 16 January 2002 ,Accepted 18 June 2002.

References 

    REFERENCES
  1. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines—similarities, differences and some implications. Value Health. 2001;4:225–250
  2. Gerdtham UG, Hertzman P, Boman G, Jönsson B. Impact of inhaled corticosteroids on asthma hospitalization in Sweden. Appl Econ. 1996;28:1591–1599
  3. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887–891
  4. Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients. Clin Ther. 1998;20:567–580
  5. Rutten-van Mölken M, Kerstjens H. Combination of inhaled corticosteroids and β 2-agonists in asthma. Clinical and economic implications. Clin Immunother. 1996;6:489–505
  6. Davis R, McTavish D. Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma. Pharmacoeconomics. 1995;7:457–470
  7. Buxton MJ. Economic evaluation studies in respiratory medicine. Respir Med. 1991;85:43–46
  8. Sullivan S, Elixhauser A, Buist AS. National Asthma Education and Prevention Program Working Group report on the cost–effectiveness of asthma care. Am J Respir Crit Care Med. 1996;154:S84–S95
  9. Drummond M, O'Brian B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997;
  10. Gold M, Siegel J, Russel L, Weinstein M. Cost–effectiveness in Health and Medicine. New York: Oxford University Press; 1996;
  11. Johannesson M. Theory and Methods of Economic Evaluation of Health Care. Dordrecht: Kluwer Academic Publishers; 1996;
  12. Spilker B. Developing guidelines for pharmacoeconomic trials. In:  Spilker B editors. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven; 1996;p. 1123–1130
  13. Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ. 1996;5:279–296
  14. Rovira, J, HARMET—The harmonisation by consensus of the methodology for economic evaluation of health care technologies in the European union, September 1997
  15. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52:1–34
  16. Boulet L-P, Cockcroft DW, Toogood J, Lacasse Y, Baskerville J, Hargreave FE. Comparative assessment of safety and efficacy of inhaled corticosteroids: report of a committee of the Canadian Thoracic Society. Eur Respir J. 1998;11:1194–1210
  17. Beasley R, Sterk PJ, Kerstjens H AM, Decramer M. Comparative studies of inhaled corticosteroids in asthma. Eur Respir J. 2001;17:579–580
  18. Swedish Council on Technology Assessment in Health Care (SBU), Behandling av astma och KOL. En systematisk kunskapsöversikt, 151, 2000
  19. Barnes PJ, Jönsson B, Klim JB. The costs of asthma. Eur Respir J. 1996;9:636–642
  20. Weiss K, Sullivan S. The economic costs of asthma. A review and conceptual model. Pharmacoeconomics. 1993;4:14–30
  21. Pearson MG, Johnson FN. Pharmacoeconomic aspects of fluticasone propionate in the treatment of asthma. Rev Contemp Pharmacother. 1998;9:591–599
  22. Lipworth BJ, Wilson AM. Dose response to inhaled corticosteroids: benefits and risks. Semin Respir Crit Care Med. 1998;19:625–646
  23. Sullivan S, Weiss K. Health economics of asthma and rhinitis. II. Assessing the value of interventions. J Allergy Clin Immunol. 2001;107:203–210
    REFERENCES FOR THE 18 REVIEWED ARTICLES
  1. Campbell LM, Simpson RJ, Turbitt ML, Richardson P DI. A comparison of the cost effectiveness of budesonide 400 μg/day and 800 μg/day in the management of mild-to-moderate asthma in general practice. Br J Med Econ. 1993;6:67–74
  2. Connett GJ, Lenney W, McConchie SM. The cost effectiveness of budesonide in severe asthmatics aged one to three years. Br J Med Econ. 1993;6:127–134
  3. Rutten-van Mölken M PMH, Van Doorslaer E KA, Jansen M CC, Van Essen-Zandvliet EE, Rutten F FH. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics. 1993;4:257–270
  4. Booth PC, Capsey LJ, Langdon CG, Wells N EJ. A comparison of the cost–effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br J Med Econ. 1995;8:65–72
  5. Rutten-van Mölken M PMH, Doorslaer E KA, Jansen M CC, Kertsjens H AM, Rutten F FH. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151:975–982
  6. Booth PC, Wells NE, Morrison AK. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. Pharmacoeconomics. 1996;10:262–268
  7. O'Byrne P, Cuddy L, Taylor DW, Birch S, Morris J, Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J. 1996;3:169–175
  8. Venables TL, McConchie S, Follows R MA. A comparison of the cost–effectiveness of budesonide and fluticasone dry-powder devices in the management of adult asthma. Br J Med Econ. 1996;10:315–323
  9. Liljas B, Ståhl E, Pauwels RA. Cost–effectiveness analysis of a dry powder inhaler (Turbuhaler) versus pressurised metered dose inhaler in patients with asthma. Pharmacoeconomics. 1997;12:267–277
  10. Williams J, Richards KA. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/DiskusTM inhaler compared with the Turbohaler™ inhaler in paediatric patients. Br J Clin Pract. 1997;51:147–153
  11. O'Reilly JF, Weir DC, Banham S, Basran GS, Boyd G, Patel KR. Is high-dose fluticasone propionate via a metered-dose inhaler and Volumatic as efficacious as nebulized budesonide in adult asthmatics?. Respir Med. 1998;92:111–117
  12. Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost–effectiveness in primary care. Respir Med. 1998;92:351–353
  13. Steinmetz KO, Volmer T, Trautmann M, Kielhorn A. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma. Clin Drug Invest. 1998;16:117–123
  14. Volmer T, Kielhorn A, Weber HH, Weissmann KJ. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naı̈ve patients with moderate asthma. Pharmacoeconomics. 1999;16:525–531
  15. Miyamoto T, Fujino S, Nakajima S, Tollemar U, Liljas B. Cost–effectiveness of budesonide Turbuhaler in the treatment of mild-to-moderate asthma in Japan. Allergol Int. 1999;48:275–285
  16. Lundbäck B, Pieters W, Johansson G, Palmqvist M, Price M, Sondhi S, et al. Cost–effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma: I–V. Pharmacoeconomics. 1999;16:1–34
  17. Lundbäck B, Jenkins C, Price M, Thwaites R. Cost–effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma. Respir Med. 2000;94:724–732
  18. Stanford RH, Edwards LD, Rickard KA. Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma. Clin Drug Invest. 2000;20:237–244

PII: S0954-6111(02)91405-8

doi: 10.1053/rmed.2002.1405

Respiratory Medicine
Volume 97, Issue 1 , Pages 1-11 , January 2003

Article Tools